Logo image of ENTO

ENTERO THERAPEUTICS INC (ENTO) Stock Overview

NASDAQ:ENTO - US33749P4081 - Common Stock

2.7 USD
+0.05 (+1.89%)
Last: 9/5/2025, 8:10:05 PM

ENTO Key Statistics, Chart & Performance

Key Statistics
52 Week High2.95
52 Week Low0.84
Market Cap4.29M
Shares1.59M
Float1.47M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)N/A
PEN/A
Fwd PEN/A
Earnings (Next)10-20 2025-10-20
IPO10-11 2016-10-11
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ENTO short term performance overview.The bars show the price performance of ENTO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

ENTO long term performance overview.The bars show the price performance of ENTO in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of ENTO is 2.7 USD. In the past month the price increased by 131.36%. In the past year, price increased by 127.85%.

ENTERO THERAPEUTICS INC / ENTO Daily stock chart

ENTO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.07 375.50B
AMGN AMGEN INC 13.01 152.70B
GILD GILEAD SCIENCES INC 14.86 142.76B
VRTX VERTEX PHARMACEUTICALS INC 23.38 101.56B
REGN REGENERON PHARMACEUTICALS 12.56 60.77B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.25B
ARGX ARGENX SE - ADR 80.99 45.95B
ONC BEONE MEDICINES LTD-ADR 5.99 40.63B
INSM INSMED INC N/A 30.67B
BNTX BIONTECH SE-ADR N/A 27.03B
NTRA NATERA INC N/A 23.06B
BIIB BIOGEN INC 8.79 20.62B

About ENTO

Company Profile

ENTO logo image Entero Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.

Company Info

ENTERO THERAPEUTICS INC

777 Yamato Road, Suite 502

Boca Raton FLORIDA US

Employees: 2

ENTO Company Website

ENTO Investor Relations

Phone: 15615897020

ENTERO THERAPEUTICS INC / ENTO FAQ

What is the stock price of ENTERO THERAPEUTICS INC today?

The current stock price of ENTO is 2.7 USD. The price increased by 1.89% in the last trading session.


What is the ticker symbol for ENTERO THERAPEUTICS INC stock?

The exchange symbol of ENTERO THERAPEUTICS INC is ENTO and it is listed on the Nasdaq exchange.


On which exchange is ENTO stock listed?

ENTO stock is listed on the Nasdaq exchange.


What is ENTERO THERAPEUTICS INC worth?

ENTERO THERAPEUTICS INC (ENTO) has a market capitalization of 4.29M USD. This makes ENTO a Nano Cap stock.


How many employees does ENTERO THERAPEUTICS INC have?

ENTERO THERAPEUTICS INC (ENTO) currently has 2 employees.


Should I buy ENTERO THERAPEUTICS INC (ENTO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ENTERO THERAPEUTICS INC (ENTO) stock pay dividends?

ENTO does not pay a dividend.


When does ENTERO THERAPEUTICS INC (ENTO) report earnings?

ENTERO THERAPEUTICS INC (ENTO) will report earnings on 2025-10-20.


ENTO Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ENTO. When comparing the yearly performance of all stocks, ENTO is one of the better performing stocks in the market, outperforming 96.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ENTO Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

ENTO Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

ENTO Ownership

Ownership
Inst Owners2.86%
Ins Owners6.12%
Short Float %N/A
Short Ratio0.04